Identification of Differentially Expressed Plasma lncRNAs As Potential Biomarkers for Breast Cancer



      Breast cancer is the most common malignant tumor in women and is not easy to diagnose. Increasing evidence has underscored that long non-coding RNAs (lncRNAs) play important regulatory roles in the occurrence and progression of many cancers, including breast cancer. We aimed to identify lncRNAs in plasma as potential biomarkers for breast cancer.

      Patients and Methods

      We analyzed the Gene Expression Omnibus (GEO) datasets GSE22820, GSE42568, and GSE65194 to identify the common differential genes between cancer tissues and adjacent tissues. Then 14 lncRNAs were identified among the common differential genes and validated by using real-time quantitative polymerase chain reaction in 92 patients with breast cancer and 100 healthy controls. Receiver operating characteristic (ROC) curves were constructed to evaluate their diagnostic value for breast cancer.


      Integrated analysis of the GEO datasets identified three significantly upregulated and 11 downregulated lncRNAs in breast cancer tissues. Compared with healthy controls, MIAT was significantly upregulated in breast cancer patient plasma, and LINC00968 and LINC01140 were significantly downregulated. ROC curve analysis suggested that these three lncRNAs can discriminate breast cancer from healthy individual with high specificity and sensitivity.


      This research identified three differentially expressed lncRNAs in breast cancer patient plasma. Our data suggest that these three lncRNAs can be used as potential diagnostic biomarkers of breast cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Bray F
        • Ferlay J
        • Soerjomataram I
        • et al.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Chen W
        • Zheng R
        • Baade PD
        • et al.
        Cancer statistics in China, 2015.
        CA Cancer J Clin. 2016; 66: 115-132
        • Harbeck N
        • Gnant M.
        Breast cancer.
        Lancet. 2017; 389: 1134-1150
        • Venema CM
        • Bense RD
        • Steenbruggen TG
        • et al.
        Consideration of breast cancer subtype in targeting the androgen receptor.
        Pharmacol Ther. 2019; 200: 135-147
        • Jiao ZY
        • Tian Q
        • Li N
        • Wang HB
        • Li KZ.
        Plasma long non-coding RNAs (lncRNAs) serve as potential biomarkers for predicting breast cancer.
        Eur Rev Med Pharmacol Sci. 2018; 22: 1994-1999
        • Patani N
        • Martin LA
        • Dowsett M.
        Biomarkers for the clinical management of breast cancer: international perspective.
        Int J Cancer. 2013; 133: 1-13
        • Klinge CM.
        Non-coding RNAs in breast cancer: intracellular and intercellular communication.
        Noncoding RNA. 2018; 4: 40
        • Kim J
        • Piao HL
        • Kim BJ
        • et al.
        Long noncoding RNA MALAT1 suppresses breast cancer metastasis.
        Nat Genet. 2018; 50: 1705-1715
        • Nagini S.
        Breast cancer: current molecular therapeutic targets and new players.
        Anticancer Agents Med Chem. 2017; 17: 152-163
        • Yan X
        • Hu Z
        • Feng Y
        • et al.
        Comprehensive genomic characterization of long non-coding RNAs across human cancers.
        Cancer Cell. 2015; 28: 529-540
        • Kondo Y
        • Shinjo K
        • Katsushima K.
        Long non-coding RNAs as an epigenetic regulator in human cancers.
        Cancer Sci. 2017; 108: 1927-1933
        • Bhan A
        • Soleimani M
        • Mandal SS.
        Long noncoding RNA and cancer: a new paradigm.
        Cancer Res. 2017; 77: 3965-3981
        • Botti G
        • Collina F
        • Scognamiglio G
        • et al.
        LncRNA HOTAIR polymorphisms association with cancer susceptibility in different tumor types.
        Curr Drug Targets. 2018; 19: 1220-1226
        • Wang J
        • Su Z
        • Lu S
        • et al.
        LncRNA HOXA-AS2 and its molecular mechanisms in human cancer.
        Clin Chim Acta. 2018; 485: 229-233
        • El-Ashmawy NE
        • Hussien FZ
        • El-Feky OA
        • Hamouda SM
        • Al-Ashmawy GM.
        Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
        Life Sci. 2020; 259118193
        • Chandra Gupta S
        • Nandan Tripathi Y
        Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets.
        Int J Cancer. 2017; 140: 1955-1967
        • Sarfi M
        • Abbastabar M
        • Khalili E.
        Long noncoding RNAs biomarker-based cancer assessment.
        J Cell Physiol. 2019; 234: 16971-16986
        • Mann J
        • Reeves HL
        • Feldstein AE.
        Liquid biopsy for liver diseases.
        Gut. 2018; 67: 2204-2212
        • Shankar GM
        • Balaj L
        • Stott SL
        • Nahed B
        • Carter BS.
        Liquid biopsy for brain tumors.
        Expert Rev Mol Diagn. 2017; 17: 943-947
        • Mader S
        • Pantel K.
        Liquid biopsy: current status and future perspectives.
        Oncol Res Treat. 2017; 40: 404-408
        • Lousada-Fernandez F
        • Rapado-Gonzalez O
        • Lopez-Cedrun JL
        • et al.
        Liquid biopsy in oral cancer.
        Int J Mol Sci. 2018; 19: 1704
        • Jing H
        • Qu X
        • Liu L
        • Xia H.
        A novel long noncoding RNA (lncRNA), LL22NC03-N64E9.1, promotes the proliferation of lung cancer cells and is a potential prognostic molecular biomarker for lung cancer.
        Med Sci Monit. 2018; 24: 4317-4323
        • Li G
        • Zhang Y
        • Mao J
        • et al.
        lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer.
        J Cell Biochem. 2019; 120: 18014-18019
        • Zhang G
        • Chi N
        • Lu Q
        • Zhu D
        • Zhuang Y
        LncRNA PTCSC3 is a biomarker for the treatment and prognosis of gastric cancer.
        Cancer Biother Radiopharm. 2020; 35: 77-81
        • Jiang N
        • Meng X
        • Mi H
        • et al.
        Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer.
        Clin Chim Acta. 2018; 486: 26-33
        • Tu C
        • Ren X
        • He J
        • et al.
        The value of LncRNA BCAR4 as a prognostic biomarker on clinical outcomes in human cancers.
        J Cancer. 2019; 10: 5992-6002
        • Misawa A
        • Takayama KI
        • Inoue S.
        Long non-coding RNAs and prostate cancer.
        Cancer Sci. 2017; 108: 2107-2114
        • Sone M
        • Hayashi T
        • Tarui H
        • et al.
        The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons.
        J Cell Sci. 2007; 120: 2498-2506
        • Alipoor FJ
        • Asadi MH
        • Torkzadeh-Mahani M.
        MIAT lncRNA is overexpressed in breast cancer and its inhibition triggers senescence and G1 arrest in MCF7 cell line.
        J Cell Biochem. 2018; 119: 6470-6481
        • Crea F
        • Venalainen E
        • Ci X
        • et al.
        The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
        Epigenomics. 2016; 8: 721-731
        • Liu Z
        • Wang H
        • Cai H
        • et al.
        Long non-coding RNA MIAT promotes growth and metastasis of colorectal cancer cells through regulation of miR-132/Derlin-1 pathway.
        Cancer Cell Int. 2018; 18: 59
        • Li Y
        • Jiang B
        • Wu X
        • et al.
        Long non-coding RNA MIAT is estrogen-responsive and promotes estrogen-induced proliferation in ER-positive breast cancer cells.
        Biochem Biophys Res Commun. 2018; 503: 45-50
        • Almnaseer ZA
        • Mourtada-Maarabouni M.
        Long noncoding RNA MIAT regulates apoptosis and the apoptotic response to chemotherapeutic agents in breast cancer cell lines.
        Biosci Rep. 2018; 38: 31
        • Li D
        • Li L
        • Cao Y
        • Chen X.
        Downregulation of LINC01140 is associated with adverse features of breast cancer.
        Oncol Lett. 2020; 19: 1157-1164
        • Sun X
        • Huang T
        • Zhang C
        • et al.
        Long non-coding RNA LINC00968 reduces cell proliferation and migration and angiogenesis in breast cancer through up-regulation of PROX1 by reducing hsa-miR-423-5p.
        Cell Cycle. 2019; 18: 1908-1924
        • Xiu DH
        • Liu GF
        • Yu SN
        • et al.
        Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2.
        J Exp Clin Cancer Res. 2019; 38: 94